浙江省人大常委会


宁波市人民代表大会常务委员会

公 告


第49号

《宁波市信息化条例》已报经浙江省第十届人民代表大会常务委员会第三十一次会议于2007年3月29日批准，现予公布，自2007年6月1日起施行。


宁波市人民代表大会常务委员会

2007年4月17日



浙江省人民代表大会常务委员会关于批准《宁波市信息化条例》的决定

（2007年3月29日浙江省第十届人民代表大会常务委员会第三十一次会议通过）

根据《中华人民共和国立法法》第六十三条第二款规定，浙江省第十届人民代表大会常务委员会第三十一次会议对宁波市第十二届人民代表大会常务委员会第三十五次会议通过的《宁波市信息化条例》进行了审议，现决定予以批准，由宁波市人民代表大会常务委员会公布施行。


宁波市信息化条例

（2006年11月29日宁波市第十二届人民代表大会常务委员会第三十五次会议通过 2007年3月29日浙江省第十届人民代表大会常务委员会第三十一次会议批准）

第一章 总 则

第一条 为推进信息化建设，加强信息化的规划与管理，促进经济社会全面协调可持续发展，根据国家有关法律、法规，结合本市实际，制定本条例。

第二条 本市行政区域内的信息化规划、信息基础设施建设、信息化工程建设、信息产业发展、信息资源开发利用、信息技术应用、信息安全保护等活动，适用本条例。

第三条 市和县（市）、区人民政府应当加强对本行政区域内信息化工作的领导，保障信息化建设与管理的合理投入，有计划、有步骤地开展信息化知识的宣传、普及与教育，加快对信息化人才的教育、培养和引进，鼓励信息化自主创新，促进信息化发展。

县（市）、区人民政府应当指定一个行政部门主管本行政区域的信息化工作。

乡镇人民政府（街道办事处）应当确定信息化工作人员，做好本行政区域的信息化工作。

第四条　市和县（市）、区信息化行政部门负责本行政区域内的信息化促进与管理工作，履行规划编制、组织协调、监督管理等职能。

电信管理等其他有关行政部门和履行公共管理职能的组织，依照《中华人民共和国电信条例》等有关法律、法规的规定，做好各自职责范围内的信息化工作。

第二章 信息化规划

第五条 信息化建设应当按照信息化发展规划有序推进。

市和县（市）、区人民政府应当将信息化发展规划列入国民经济和社会发展总体规划。

第六条 编制信息化发展规划，应当从实际出发，符合经济社会发展的实际需要，遵循信息化发展规律，加强统筹协调，增强规划的指导性和可操作性。

信息化发展规划由市和县（市）、区信息化行政部门会同同级发展和改革行政部门组织编制，经征求上级信息化行政部门和电信管理机构意见后，由同级人民政府批准实施。

其他有关部门和单位编制的专项信息化发展（建设）规划，应当符合信息化发展规划的要求，并在规划公布之前报本级信息化行政部门备案。

第七条 信息化发展规划生效后，任何单位和个人不得擅自变更。确需调整的，应当按照规定的程序办理审批手续。

信息化发展规划及其执行情况，应当由市或县（市）、区信息化行政部门通过公共媒体向社会公开，接受社会各界的咨询和监督。

第三章　信息基础设施及信息化工程

第八条 新建、扩建或者改建信息基础设施，应当符合城市总体规划和村镇建设规划。

第九条 信息基础设施应当实行集约化建设和管理。城市公共设施的建设、管理单位应当为电信经营者共享信息基础设施提供便利。

建筑物内的电信管线和配线设施以及建设项目用地范围内的电信管道，应当纳入建设项目的设计文件，由建设单位随建设项目同时施工。建筑物建成后驻地网的建设应当尊重业主选择，实行电信业务经营者公平竞争。

设置无线通信基站应当依法实行环境影响评价。

第十条 信息基础设施建设应当避免重复浪费。电信网之间应当按照技术可行和相互配合的原则，实行互联互通。

第十一条　信息化工程建设应当符合信息化发展规划。逐步建立信息化工程的绩效评估体系。

政府投资的信息化工程应当遵循资源共享、统一标准的原则进行建设。

市和县（市）、区人民政府应当加强对政府投资的信息化工程项目的统筹规划和监督管理，并积极引导各种社会资金投资建设信息化工程。

第十二条　政府投资的信息化工程建设应当依法通过招标投标或政府采购进行。

信息化行政部门对信息化工程的招标投标活动实施指导和监督。

第十三条　政府投资的信息化工程，按照有关规定实行项目储备制度。政府年度投资计划内的信息化工程项目一般应当从政府投资项目储备库中选取。

有关部门在批复项目建议书、可行性研究报告前应当征询同级信息化行政部门的意见。

第十四条　非政府投资的重大公共基础性信息化工程或信息安全工程，建设单位应当自竣工之日起三个月内将设计和施工方案报市或县（市）、区信息化行政部门备案。

前款规定的重大公共基础性信息化工程或信息安全工程的具体范围由市信息化行政部门确定并公布。

第十五条　信息化工程竣工后，建设单位应当按照国家标准或者行业标准进行性能测试，并按照国家有关规定进行验收。其中，政府投资的信息化工程项目竣工后，应当由信息化行政部门组织专项验收，并由发展和改革行政部门组织竣工验收后，方可交付使用。

第四章　信息产业发展

第十六条 市信息化行政部门应当根据国家有关产业政策和本市实际，确定本市信息产业发展重点，定期发布产业发展导向目录，引导信息产业发展。

第十七条 市和县（市）、区人民政府应当制定具体措施，加大信息产业发展资金投入，并对信息产业重点项目给予扶持。逐步建立信息产业风险投资机制，鼓励境内外企业、其他经济组织和个人投资信息产业。

第十八条 市和县（市）、区人民政府应当根据规划加强信息产业基地和信息产业园区建设。

第十九条 企业从事电子信息产品设计制造、软件开发等活动，应当执行国家、行业及地方规定的强制性标准。没有强制性标准的，鼓励制定先进的企业标准。

第二十条 鼓励信息化行业协会、社会中介机构以及其他社会组织和个人依法从事信息化人才培训、咨询监理、信息技术推广应用、信息资源开发利用等活动，其合法权益受法律保护。

第五章 信息资源开发利用

第二十一条 政务信息资源的开发利用应当按照统筹规划、统一标准、共享和保护相协调的要求，实现资源共享。涉及保密规定的，按照国家有关规定办理。

本市建立电子政务技术标准实施机制。市信息化行政部门会同有关部门，根据信息化发展规划要求，组织编制本市电子政务技术标准实施指南和信息资源共享目录。

第二十二条 国家机关和社会公共服务组织应当利用信息技术采集、加工、存储、分析、使用各类业务信息，建立业务信息资源库及应用系统。

市和县（市）、区人民政府应当统一组织有关部门开发建设本行政区域内的人口、法人单位、地理空间等重点基础性数据库。

第二十三条 各级人民政府及职能部门应当扶持和鼓励社会力量开发信息资源。支持信用中介机构依法采集、整合企业与个人信用信息，为社会提供信用征信、评价评级、信息管理服务。

第二十四条 收集社会组织或个人的信息应当通过合法手段获取，并在信息提供者许可的范围内合理利用。

未经信息权利人许可或授权，任何单位和个人不得擅自删除、修改信息网络系统中存储的信息。法律、法规另有规定的除外。

第二十五条　市和县（市）、区人民政府应当建立本级政务信息交换平台。各级人民政府及职能部门、社会公共服务组织应当按照政务信息资源共享的规定，及时向本级政务信息交换平台提供有关信息，并负责该信息的更新。

本市政务信息资源共享的具体办法由市人民政府另行规定。

第二十六条　各级人民政府及职能部门、其他履行公共管理职能的组织，应当按照有关规定做好政务信息公开工作。

除法律、法规另有规定外，凡涉及经济社会管理、提供公共服务以及其他与公众密切相关的政务信息，有关单位应当自制作或获得该信息之日起十日内在政府门户网站或有关子网站上予以公开。

第六章 信息技术应用

第二十七条 市和县（市）、区人民政府应当统筹协调和领导本行政区域信息技术推广应用工作，建立和完善信息技术推广应用体系，推进各地区、各领域信息化平衡协调发展。

第二十八条 市和县（市）、区人民政府应当制定具体的扶持政策和措施，鼓励、引导信息技术在经济社会各领域的推广应用，加强农村信息基础设施建设和农民信息化知识的培训，建立完善农村信息服务体系，为农民生产生活提供适用的市场、科技、教育、文化、卫生、保健等信息服务。

科技、技术改造、农业发展等专项资金中应当有一定比例用于引导和扶持相关领域信息技术的推广应用。

第二十九条 市和县（市）、区人民政府应当引导社会逐步建立、完善信用体系和网上结算、物流配送等信息系统，推进电子商务发展。

第三十条 教育科研、医疗卫生、就业和社会保障、金融保险等社会公共服务组织，应当根据本单位实际情况，充分应用信息技术，提高社会公共事业服务水平。

新闻出版、广播影视、文学艺术等行业应当加快信息化建设步伐，营造积极健康的网络文化，促进公共文化信息服务体系的建立。

第三十一条 企业和其他经济组织应当在研发、生产、经营和管理等方面广泛应用信息技术，促进技术进步和产业升级。

鼓励有条件的企业和其他经济组织参与信息技术和信息产品国家标准的制定。对参与国家标准制定的企业，政府应当予以奖励。

第七章 信息安全保护

第三十二条　信息化行政部门应当按照有关规定做好信息安全保护的协调、指导、服务和相关管理工作。

公安、国家安全、保密等行政部门应当按照有关规定，在各自职责范围内做好信息安全保护工作。

第三十三条 信息系统的主管部门和运营、使用单位应当根据国家有关规定，确定本部门、本单位信息系统的安全等级。

信息系统的安全系统必须使用依法认可的信息安全专用产品，并与主体工程同时设计、同时施工、同时投入使用。

信息系统在投入使用前，建设单位应当委托符合国家规定条件的信息安全测评机构对其系统进行安全性测评，测评合格的方可投入使用。

第三十四条 信息系统的主管部门和运营、使用单位应当建立信息安全保护管理制度，落实信息安全保护技术措施，并进行相应的安全系统建设。

涉及公共利益的信息系统，其主管部门和运营、使用单位应当落实安全管理责任，制定信息安全应急预案，加强信息安全容灾建设，保障信息安全。

第三十五条 信息化、公安、国家安全、保密等行政部门应当建立信息安全情况通报和应急处理协调机制，不断提高信息系统的安全防御能力和处理信息安全突发事件的能力。

发生信息安全事故的单位和个人应当按照有关规定及时向信息化行政部门、公安机关等有关部门报告，有关部门应当及时按照规定处理。

第三十六条 任何单位和个人不得利用信息系统从事危害国家安全，损害国家利益、集体利益和公民合法权益的活动，不得危害信息系统的安全。

第八章 法律责任

第三十七条 违反本条例规定，法律、法规已有处罚规定的，依照法律、法规的有关规定处罚。

第三十八条 违反本条例第六条第三款、第七条第一款规定的，由信息化行政部门责令改正，并对有关单位予以通报批评。

第三十九条 违反本条例第十四条第一款规定的，由信息化行政部门责令改正，并予以警告。

第四十条 违反本条例第三十三条规定的，由公安机关责令改正，予以警告，并可处一千元以上五千元以下的罚款。

第四十一条 信息化行政部门和其他有关部门及其工作人员在信息化管理工作中徇私舞弊、滥用职权、玩忽职守的，由其上级机关或者所在单位责令改正；对直接负责的主管人员和其他直接责任人员，由其所在单位或者上级机关依法给予行政处分；构成犯罪的，依法追究其刑事责任。

第九章 附 则

第四十二条 本条例下列用语的含义：

信息基础设施，主要包括承载通信传输介质的通信管网、用户驻地网、无线通信基站以及相关辅助设施；

信息化工程，是指以计算机技术和通信技术为主要手段的信息系统建设、信息资源开发等工程；

信息产业，是指电子信息产品制造业、软件业、通信业及相关的信息服务业；

信息资源，是指本市内的组织和个人在履行职责、机构运行或开展社会活动时所产生和使用的、可以在一定范围内公开并具有一定社会应用价值的信息；

信息系统，是指由计算机、信息网络及其配套的设施、设备构成的，按照一定的应用目标和规则对信息进行存储、传输、处理的运行体系。

第四十三条 本条例自2007年6月1日起施行。







State Food and Drug Administration，State Administration for Industry and Commerceof the People’s Republic of China


Provisions for Drug Advertisement Examination



(SFDA Decree No. 27)

The Provisions for Drug Advertisement Examination, adopted by the State Food and Drug Administration and the State Administration for Industry and Commerce of the People’s Republic of China, is now issued in the decree sequence number of the State Food and Drug Administration. The Provisions shall go into effect as of the date of May 1, 2007.



Shao Mingli
Commissioner
State Food and Drug Administration

Zhou Bohua
Minister
State Administration for Industry and Commerceof the People’s Republic of China

March 13, 2007





Provisions for Drug Advertisement Examination


Article 1 The Provisions are formulated for the purposes of strengthening regulation on drug advertisements and ensuring the authenticity and legality of drug advertisements in accordance with the Advertisement Law of the People’s Republic of China (hereinafter referred to as Advertisement Law), the Drug Administration Law of the People's Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for the Implementation of Drug Administration Law of the People's Republic of China (hereinafter referred to as Regulations for the Implementation of Drug Administration Law) and other regulations related to supervision on advertisements and drugs.

Article 2 A drug advertisement refers to any advertisement published through various media or forms containing drug name, indications (functions) or other relevant contents, and shall be examined and approved in accordance with the Provisions.

Where only the names of non-prescription drugs (including adopted names and trade names) are publicized or only the names of prescription drugs (including adopted names and trade names) are publicized in professional medical or pharmaceutical journals, the examination is not required.

Article 3 The drug advertisement applied for examination shall be approved provided that it conforms to the following laws, regulations and related provisions:
(1) Advertisement Law;
(2) Drug Administration Law;
(3) Regulations for Implementation of Drug Administration Law;
(4) Criteria for Examining and Publishing Drug Advertisement;
(5) Other provisions of the State on advertisement regulation.

Article 4 The drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government are the drug advertisement examination authorities responsible for examining drug advertisements within their administrative regions. The administrative departments for industry and commerce at or above the county level are supervision and control authorities for drug advertisements.

Article 5 The State Food and Drug Administration shall guide and supervise the examination conducted by drug advertisement examination authorities and punish, in accordance with law, the examination authorities that have violated the Provisions.

Article 6 An applicant for a drug advertisement approval number must be an eligible drug manufacturer or distributor. Where the applicant is a drug distributor, the consent of the drug manufacturer is required.

An applicant may entrust an agent with the application for a drug advertisement approval number.

Article 7 An application for a drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the drug manufacturer is located.

An application for an import drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the agent of the import drug is located.

Article 8 Where a drug manufacturer or distributor applies for a drug advertisement approval number, it shall submit an Application Form for Drug Advertisement (Appendix 1) with sample manuscript (sample film or sample record) of which the content is consistent with that to be published attached, and an electronic document of drug advertisement application. It shall also submit the following proof documents that are authentic, legal and valid:
(1) Copy of the Business License of the applicant;
(2) Copy of the Drug Manufacturing Certificate or the Drug Supply Certificate of the applicant;
(3) Where the applicant is a drug distributor, the original document proving that the drug manufacturer authorizes the drug distributor to be the applicant shall be submitted;
(4) Where an agent submits an application for a drug advertisement approval number on behalf of the applicant, an original authorization letter given by the applicant to the agent, a copy of business license of the agent and other documents proving the subject’s qualifications shall be submitted;
(5) Copies of the drug approval document (including Import Drug License or Pharmaceutical Product License), copy of approved insert sheet, and label and insert sheet used in practice;
(6) For non-prescription drug advertisement, a copy of registration certificate of non-prescription drug examination or copies of relevant certificates is required;
(7) Where an applicant applies for an import drug advertisement approval number, copies of qualification certificates of the agent of the import drug shall be submitted;
(8) Where the trade name, registered trademark and patent of the drug are involved in an advertisement, copies of the valid certificates and other relevant documents proving the authenticity of the advertisement shall be submitted.

The copy of any approval document prescribed in this Article shall be sealed by the document holder.

Article 9 An advertisement application by an enterprise for a drug shall not be accepted by the drug advertisement examination authorities under any of the following circumstances:
(1) Any of the circumstances under which the application shall be rejected as prescribed in Article 20, Article 22 and Article 23 of the Provisions;
(2) An administrative procedure to withdraw a drug advertisement approval number is in process.

Article 10 After receiving an application for drug advertisement approval number, where the dossier is complete and in conformity with statutory requirements, the drug advertisement examination authority shall issue an Acceptance Notice of Drug Advertisement; where the dossier is incomplete or not conforming to the statutory requirements, one notification on all the content to be supplemented or corrected shall be given to the applicant on the spot or within five working days; if the notification to the applicant is not issued within the timeline, the application is deemed as being accepted upon the date when the dossier is received.

Article 11 Within ten working days upon accepting an application, the drug advertisement examination authority shall check the authenticity, legality and validity of the documents submitted by the applicant, and shall examine the advertisement content in accordance with law. For the drug advertisement in conformity with statutory requirements, a drug advertisement approval number shall be issued; for those not in conformity with statutory requirements, the authority shall make a decision of not issuing a drug advertisement approval number and notify the applicant of the decision with reasons in written form and the applicant’s right to apply for administrative reconsideration or to bring an administrative suit by law.

For approved drug advertisement, the drug advertisement examination authority shall report to the State Food and Drug Administration for records and send the approved Application Form for Drug Advertisement to the authority responsible for advertisement supervision and control at the same level for records. Where there is any problem in the drug advertisement reported to the State Food and Drug Administration for records, the State Food and Drug Administration shall instruct the drug advertisement examination authority to correct it.

The drug regulatory departments shall announce the approved drug advertisement timely.

Article 12 Where a drug advertisement is to be published in the province, autonomous region or municipality directly under the Central Government other than the place where the drug manufacturer and the agent of the import drug are located (hereinafter referred to as “non-local drug advertisement”), it shall, before being published, be submitted for records to the drug advertisement examination authority in the place where the advertisement is to be published.

Article 13 The following materials for non-local drug advertisement shall be submitted for record:
(1) Copy of the Application Form for Drug Advertisement;
(2) Copy of the approved drug insert sheet;
(3) For television or audio broadcast advertisement, it is required to submit the audio tape, compact disc or other medium carrier on which the content is consistent with the approved content.

The copy of any document prescribed in this Article shall be sealed by the document holder.

Article 14 For application for putting non-local drug advertisement on record in accordance with Articles 12 and Article 13 of the Provisions, the drug advertisement examination authority shall, within five working days after accepting the application, put such drug advertisement on record, endorse the word “recorded” on the Application Form for Drug Advertisement, affix the seal specific for drug advertisement examination and send the form to the supervision and control authorities for advertisements at the same level for future reference.

Where the drug advertisement examination authority of a place where a drug advertisement is to be put on record finds that the drug advertisement is not conformed with the relevant provisions, it shall fill in the Opinion on the Record of Drug Advertisement Examination (Appendix 2), submit it to the original drug advertisement examination authority for check, and copy it to the State Food and Drug Administration.

Within five working days upon receiving the Opinion on the Record of Drug Advertisement Examination, the original drug advertisement examination authority shall give its opinions to the drug advertisement examination authority of the place where the drug advertisement is to be put on record. Where no consensus is achieved between the original drug advertisement examination authority and the drug advertisement examination authority of the place where a drug advertisement is to be put on record, the case may be submitted to the State Food and Drug Administration that shall make a final judgment.

Article 15 The valid term of a drug advertisement approval number is one year. It shall become invalid upon expiration.

Article 16 The content of an approved drug advertisement is not allowed to be changed when being published. Where any change to the drug advertisement is needed, a new drug advertisement approval number shall be obtained.

Article 17 Where an advertisement applicant publishes a drug advertisement by itself, it shall keep the original Application Form for Drug Advertisement for two years for future check.

Where an advertisement publisher or advertising operator is authorized by the applicant to publish a drug advertisement, it shall check the original Application Form for Drug Advertisement, publish the advertisement in accordance with the approved content and keep a copy of the Applicant Form for Drug Advertisement for two years for future check.

Article 18 Where there is any of the following circumstances for an approved drug advertisement, the original drug advertisement examination authority shall issue a Notice of Drug Advertisement Re-examination (Appendix 3) and conduct the re-examination. The drug advertisement may continue to be published during the re-examination.

(1) The State Food and Drug Administration finds that the content of the drug advertisement approved by the drug advertisement examination authority is not in conformity with the provisions;
(2) A supervision and control authority for advertisement at or above provincial level makes a re-examination proposal;
(3) Other circumstances where a re-examination is required by a drug advertisement examination authority.

After re-examination, where the drug advertisement is not in conformity to the statutory requirements, the Application Form for Drug Advertisement shall be taken back and the original drug advertisement approval number shall become invalid.

Article 19 Drug advertisement examination authorities shall cancel the drug advertisement approval number in any of the following circumstances:
(1) Where a Drug Manufacturing Certificate or the Drug Supply Certificate is revoked;
(2) Where a drug approval document is withdrawn or cancelled;
(3) Where the State Food and Drug Administration or the drug regulatory department of the province, autonomous region or municipality directly under the Central Government instructs to stop the production, sales and use of the drug.

Article 20 For any alteration to the approved content of a drug advertisement for false propaganda, the drug regulatory departments shall instruct to stop the publication of the advertisement immediately, revoke the drug advertisement approval number, and shall not accept any application for advertisement of the drug within one year.

Article 21 Where any illegal advertisement in which the scope of indications (functions) of the drug is expanded without authorization, the therapeutic effectiveness is exaggerated extremely, or which seriously cheats or misleads the customers, is found, the drug regulatory department at or above the provincial level shall take mandatory administrative measures to suspend the sales of the drug within their administrative area and order the enterprise that illegally publishes the drug advertisement to issue a correction notice in relevant local media.

After the enterprise that illegally publishes the drug advertisement issues a correction notice as required, the drug regulatory department at or above the provincial level shall make a decision on lifting the mandatory administrative measures within 15 working days; where it is necessary to test the drug, the drug regulatory departments shall determine whether to lift the mandatory administrative measures within 15 days as from the day when the test report is issued.

Article 22 Where a drug advertisement application providing false materials is found by the drug advertisement examination authority during the examination, no further application of the enterprise in respect of the advertisement of the drug shall be accepted within one year.

Article 23 Where a drug advertisement with an approval number is found by the drug advertisement examination authority to have provided false materials, such drug advertisement approval number shall be revoked and no further application from the enterprise in respect of the advertisement of the drug shall be accepted within three years.

Article 24 Any drug advertisement, of which the approval number is taken back, cancelled or revoked in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, shall be discontinued for publication immediately; non-local drug advertisement examination authorities shall stop filing the record of the advertisement of the enterprise with the drug advertisement approval number.

Where a drug advertisement examination authority takes back, cancels or withdraws a drug advertisement approval number in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, it shall notify the supervision and control authority for advertisements at the same level within five working days from the day when the administrative decision on the matter is made; the supervision and control authority for advertisements shall handle it in accordance with law.

Article 25 Where a non-local drug advertisement is found not put on record in the drug advertisement examination authority of the place where it is published, the authority shall instruct to file its record within a time limit. If the record is not filed within the time limit, the drug advertisement in the above-mentioned place shall be suspended.

Article 26 The drug regulatory department at or above the county level shall monitor and check the publishing of drug advertisement that has been examined and approved. For any illegal drug advertisements, drug regulatory departments at all levels shall fill in the Notice on the Transfer of Illegal Drug Advertisement (Appendix 4) and transfer it to an supervision and control authority for advertisements at the same level together with such materials as samples of illegal drug advertisement; where the content of approved non-local drug advertisement is altered without permission, the drug advertisement examination authority of the place where the advertisement is published shall advise the original drug advertisement examination authority to revoke its approval number in accordance with Article 92 of the Drug Administration Law and Article 20 of the Provisions.

Article 27 Where an illegal drug advertisement is published and the circumstances are serious, the drug regulatory department of province, autonomous region or municipality directly under the Central Government shall announce the matter to the public and timely report it to the State Food and Drug Administration. The State Food and Drug Administration shall summarize and release the collected information periodically.

Where any false or illegal drug advertisement is published and the circumstances are serious, it shall be announced to the public jointly by the State Administration for Industry and Commerce and the State Food and Drug Administration if necessary.

Article 28 For any drug advertisement published without approval, or the contents published inconsistent with the approved ones, the supervision and control authority for advertisements shall impose a punishment in accordance with Article 43 of the Advertisement Law; where it constitutes false advertisement or misleading propaganda, the supervision and control authorities for advertisements shall impose a punishment in accordance with Article 37 of the Advertisement Law and Article 24 of Anti-Unfair Competitions Law.

In the process of investigation of an illegal drug advertisement, where there is a need to affirm any drug technical information, the supervision and control authority for advertisements shall notify the drug regulatory department at or above the provincial level. The drug regulatory department at or above the provincial level shall give the affirmation result to the supervision and control authorities for advertisements within ten working days after receiving the notification.

Article 29 The staff members that examine and supervise drug advertisements shall be trained in such laws and regulations as the Advertisement Law and the Drug Administration Law. Where the staff members in drug advertisement examination department or in supervision and control authority for drug advertisements neglect their duty, abuse their power, or practice favoritism and commit irregularities, they shall be given an administrative sanction in accordance with law. If a crime is constituted, they shall be investigated for their criminal liabilities in accordance with law.

Article 30 A drug advertisement approval number shall be “X Yao Guang Shen (Shi) No. 0000000000", “X Yao Guang Shen (Sheng) No. 0000000000", “X Yao Guang Shen (Wen) No. 0000000000". “X” is the abbreviation for a province, autonomous region or municipality directly under the Central Government. “0000000000” is a number with ten digits, in which the first six represent year and month of the examination, and the last four represent advertisement approval sequence number. “Shi”, “Sheng” or “Wen” represents certain classification code used in advertising media.

Article 31 These Provisions shall come into force as of May 1, 2007. The Provisions for Drug Advertisement Examination issued by the State Administration for Industry and Commerce and the Ministry of Health (Decree of State Administration for Industry and Commerce No. 25) on March 22, 1995 shall be annulled therefrom.